To match an exact phrase, use quotation marks around the search term. eg. "Parliamentary Estate". Use "OR" or "AND" as link words to form more complex queries.


Keep yourself up-to-date with the latest developments by exploring our subscription options to receive notifications direct to your inbox

Speech in Commons Chamber - Tue 04 Jul 2017
Oral Answers to Questions

Speech Link

View all Jeremy Lefroy (Con - Stafford) contributions to the debate on: Oral Answers to Questions

Speech in Commons Chamber - Tue 27 Jun 2017
NHS Shared Business Services

Speech Link

View all Jeremy Lefroy (Con - Stafford) contributions to the debate on: NHS Shared Business Services

Written Question
European Medicines Agency
Monday 24th April 2017

Asked by: Jeremy Lefroy (Conservative - Stafford)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health, what representations he has made to his EU counterparts on the presence of the European Medicines Agency in the UK after the UK leaves the EU.

Answered by David Mowat

The European Medicines Agency’s (EMA) future location is not an issue that falls within the United Kingdom’s own competence but will be decided by the 27 remaining European Union member states. The Government is fully assessing how the UK’s decision to leave the European Union will impact on medicines regulation in the UK, including the potential relocation of the EMA. Whatever the future relationship between the UK and EMA, the Government will work to ensure that patient access to medicines will not be adversely impacted.


Written Question
European Medicines Agency
Monday 24th April 2017

Asked by: Jeremy Lefroy (Conservative - Stafford)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health, what representations he has made to his EU counterparts on the UK remaining a member of the European Medicines Agency after the UK leaves the EU.

Answered by David Mowat

The Government is fully assessing how the United Kingdom’s decision to leave the European Union will impact on medicines regulation in the UK. This includes the UK’s future membership with the European Medicines Agency which will be considered in upcoming negotiations between the UK and EU.


Speech in Westminster Hall - Tue 07 Mar 2017
O’Neill Review

Speech Link

View all Jeremy Lefroy (Con - Stafford) contributions to the debate on: O’Neill Review

Speech in Commons Chamber - Mon 27 Feb 2017
NHS Shared Business Services

Speech Link

View all Jeremy Lefroy (Con - Stafford) contributions to the debate on: NHS Shared Business Services

Speech in Commons Chamber - Tue 20 Dec 2016
Oral Answers to Questions

Speech Link

View all Jeremy Lefroy (Con - Stafford) contributions to the debate on: Oral Answers to Questions

Written Question
Lutetium Therapy
Monday 21st November 2016

Asked by: Jeremy Lefroy (Conservative - Stafford)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health, if he will take steps to review the decision to remove Lutetium-177 octreotate therapy treatments from the Cancer Drugs Fund list.

Answered by Baroness Blackwood of North Oxford

I refer the hon. Member to the Answer given by the then Parliamentary Under-Secretary of State for Life Sciences (George Freeman) on 12 July 2016 to Question 41736.


Written Question
Nurses: Training
Friday 18th November 2016

Asked by: Jeremy Lefroy (Conservative - Stafford)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health, what his Department's national three-to-five strategy is for supporting the training and development of advanced paediatric and neonatal nurse practitioners, to enable skilled acute care for infants, children and young people close to home.

Answered by Philip Dunne

The Department does not have a dedicated three to five strategy for supporting the training and development of advanced paediatric and neonatal nurse practitioners.

It is Health Education England’s (HEE) responsibility to ensure that there is sufficient future supply of staff, including those needed in specialist fields such as this, to meet the workforce requirements of the English health system.

As part of its ongoing work HEE continually looks to ensure that staff groups, such as those highlighted, have the correct planned workforce growth, consider whether new roles are required and ensure that existing undergraduate training and education meets the needs of both students and patients.

At a local level, it is the responsibility of National Health Service organisations to ensure that their staff, through Continuing Professional Development, have the ongoing skills required to deliver safe and effective care to patients.


Written Question
Hospices: Children
Thursday 27th October 2016

Asked by: Jeremy Lefroy (Conservative - Stafford)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health, what plans he has to formalise the children's hospice grant for 2017-18.

Answered by David Mowat

The Department provided grant funding in 2013-16 to Together for Short Lives, the organisation supporting children’s hospices, to support the Transition Taskforce. The Taskforce provides guidance and training that supports good transitions locally between children’s and adult services for those with life-limiting conditions or needing palliative care.

NHS England is continuing to prioritise funding for the children’s hospice grants programme at the current level. NHS England has been engaging with children’s hospices through Together for Short Lives prior to a consultation on the allocation method for the 2017-18 grant.